These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1219 related items for PubMed ID: 16424172

  • 1. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP, Gibbs KD, Ostrand-Rosenberg S.
    J Immunol; 2006 Feb 01; 176(3):1447-55. PubMed ID: 16424172
    [Abstract] [Full Text] [Related]

  • 2. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A, Grees M, Cafri G, Bassan D, Eichmüller SB, Tzehoval E, Utikal J, Umansky V, Eisenbach L.
    Int J Cancer; 2019 Feb 15; 144(4):909-921. PubMed ID: 30106470
    [Abstract] [Full Text] [Related]

  • 3. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y, Koido S, Ohana M, Liu C, Gong J.
    J Immunol; 2005 Feb 01; 174(3):1274-80. PubMed ID: 15661883
    [Abstract] [Full Text] [Related]

  • 4. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
    Ilkovitch D, Ostrand-Rosenberg S.
    Cancer Immunol Immunother; 2004 Jun 01; 53(6):525-32. PubMed ID: 14730400
    [Abstract] [Full Text] [Related]

  • 5. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo.
    Kleindienst P, Brocker T.
    J Immunol; 2003 Mar 15; 170(6):2817-23. PubMed ID: 12626531
    [Abstract] [Full Text] [Related]

  • 6. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells.
    Schnell S, Young JW, Houghton AN, Sadelain M.
    J Immunol; 2000 Feb 01; 164(3):1243-50. PubMed ID: 10640737
    [Abstract] [Full Text] [Related]

  • 7. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
    Herrera OB, Brett S, Lechler RI.
    Vaccine; 2002 Dec 13; 21(3-4):231-42. PubMed ID: 12450698
    [Abstract] [Full Text] [Related]

  • 8. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L.
    J Immunol; 2004 Feb 15; 172(4):2126-36. PubMed ID: 14764678
    [Abstract] [Full Text] [Related]

  • 9. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
    Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C, Green S, Miloradovic L, Drane D, Davis ID, Villadangos J, Shortman K, Maraskovsky E, Cebon J.
    Blood; 2005 Mar 15; 105(6):2465-72. PubMed ID: 15546948
    [Abstract] [Full Text] [Related]

  • 10. Major histocompatibility complex (MHC) class II-peptide complexes arrive at the plasma membrane in cholesterol-rich microclusters.
    Bosch B, Heipertz EL, Drake JR, Roche PA.
    J Biol Chem; 2013 May 10; 288(19):13236-42. PubMed ID: 23532855
    [Abstract] [Full Text] [Related]

  • 11. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
    Zhou G, Ding ZC, Fu J, Levitsky HI.
    J Immunol; 2011 Feb 15; 186(4):2148-55. PubMed ID: 21242518
    [Abstract] [Full Text] [Related]

  • 12. Activation of Dendritic Cells Alters the Mechanism of MHC Class II Antigen Presentation to CD4 T Cells.
    Cho KJ, Ishido S, Eisenlohr LC, Roche PA.
    J Immunol; 2020 Mar 15; 204(6):1621-1629. PubMed ID: 31996461
    [Abstract] [Full Text] [Related]

  • 13. Immune complex-mediated antigen presentation induces tumor immunity.
    Rafiq K, Bergtold A, Clynes R.
    J Clin Invest; 2002 Jul 15; 110(1):71-9. PubMed ID: 12093890
    [Abstract] [Full Text] [Related]

  • 14. Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines.
    Dolan BP, Phelan TP, Ilkovitch D, Qi L, Wade WF, Laufer TM, Ostrand-Rosenberg S.
    J Immunol; 2004 Jan 15; 172(2):907-14. PubMed ID: 14707062
    [Abstract] [Full Text] [Related]

  • 15. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
    Machy P, Serre K, Baillet M, Leserman L.
    J Immunol; 2002 Feb 01; 168(3):1172-80. PubMed ID: 11801652
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
    Dissanayake SK, Tuera N, Ostrand-Rosenberg S.
    J Immunol; 2005 Feb 15; 174(4):1811-9. PubMed ID: 15699107
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity.
    Derouazi M, Di Berardino-Besson W, Belnoue E, Hoepner S, Walther R, Benkhoucha M, Teta P, Dufour Y, Yacoub Maroun C, Salazar AM, Martinvalet D, Dietrich PY, Walker PR.
    Cancer Res; 2015 Aug 01; 75(15):3020-31. PubMed ID: 26116496
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.